United States

Palatin Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets

Lead Product(s): Bremelanotide

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: AMAG Pharmaceuticals

Deal Size: $16.3 million Upfront Cash: $12.0 million

Deal Type: Divestment July 27, 2020

Details:

Under the terms of the termination agreement, all of AMAG’s rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin.

Nurx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

TherapeuticsMD and Nurx Expand Access to ANNOVERA®

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 15, 2020

Details:

The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi™ in Contraception

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The final data analysis demonstrated a cumulative pregnancy rate of 13.7% over seven cycles of use in Phexxi group.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

U.S. FDA Approves Evofem Biosciences' Phexxi™ (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescri...

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Data demonstrate high efficacy rates of more than 93% when Phexxi is used as directed, also underscore the sexual satisfaction and lubricating factors experienced by women in the AMPOWER trial.

Afaxys Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

TherapeuticsMD and Afaxys Enter Into Agreement

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticsMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 13, 2020

Details:

The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company

Lead Product(s): Etonogestrel

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nexplanon

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: NewCo

Deal Size: $9.0 million Upfront Cash: Undisclosed

Deal Type: Divestment February 05, 2020

Details:

Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely

Lead Product(s): Estradiol,Nomegestrol Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 22, 2020

Details:

Theramex currently markets Zoely® in eleven European countries, and this transaction will bring the total number of more than 50 on a global basis. MSD retains rights in the United States and Canada.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Palatin Technologies

AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets

Nurx

TherapeuticsMD and Nurx Expand Access to ANNOVERA®

Evofem Biosciences

Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi™ in Contraception

Evofem Biosciences

U.S. FDA Approves Evofem Biosciences' Phexxi™ (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescri...

Afaxys Pharma

TherapeuticsMD and Afaxys Enter Into Agreement

Merck & Co. Inc.

Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company

Merck & Co. Inc.

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely